Cramer noted that investors are skirting Johnson & Johnson (NYSE:JNJ) because of worries regarding Robert Kennedy Jr., as he ...

Treatment-resistant schizophrenia is a disabling illness, affecting approximately 8 million people worldwide with profound ...

Six defendants, including LaNicholas Rollins, Juan Miguel Nation, Juan Pierre Nation, Demetrius Preyer, Devante McKinney, and ...

U.S. health officials are announcing an effort to phase out ingestible fluoride supplements used to strengthen children’s ...

The Food and Drug Administration says that a prominent medical contrarian and critic of the drug industry will head its ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...

But even with the extra costs, which the medical-technology and drug company JNJ estimates to be about $400 million, Johnson & Johnson still raised its outlook for sales in 2025, while keeping its ...

A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser ...

Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration for its FcRn blocker Imaavy (nipocalimab-aahu) in generalised myasthenia gravis (gMG). The drug has been ...

Learn more about this approval in Johnson & Johnson's news release here ... and potentially life-changing treatment option. "FDA's approval of IMAAVY TM (nipocalimab-aahu) is an important step in ...